# Clinical Cases: Functional and Integrative Health

## Case 1: Chronic Fatigue with Integrative Approach

### Patient Presentation
**Demographics:** 38-year-old female marketing executive

**Chief Complaint:** "I've been exhausted for over a year and nothing seems to help."

**History of Present Illness:**
The patient presents with a 14-month history of debilitating fatigue that has progressively worsened despite adequate sleep duration. She reports sleeping 8-9 hours nightly but waking unrefreshed. Her fatigue is accompanied by cognitive difficulties she describes as "brain fog," including poor concentration, word-finding difficulties, and short-term memory lapses that have begun affecting her work performance.

She has seen her primary care physician and an endocrinologist, with standard bloodwork including CBC, CMP, TSH, and hemoglobin A1c all returning within normal limits. She reports intermittent low-grade headaches, diffuse myalgias, and a sensation of swollen lymph nodes in her neck that wax and wane. She denies fever, weight loss, or night sweats.

Her symptoms began approximately two months after a confirmed COVID-19 infection (mild, managed at home). She has tried various over-the-counter supplements without sustained improvement. She rates her energy as 3/10 on most days, compared to her baseline of 8/10 prior to illness.

**Past Medical History:**
- COVID-19 infection (14 months ago, mild course)
- Seasonal allergies
- Anxiety disorder (well-controlled)

**Medications:**
- Escitalopram 10 mg daily
- Cetirizine 10 mg as needed
- Multivitamin daily

**Social History:**
- Non-smoker, occasional alcohol (1-2 glasses of wine per week)
- Sedentary due to fatigue (previously ran 3x/week)
- High-stress job with long hours
- Lives with partner, no children
- Diet: mostly processed/convenience foods due to fatigue

**Family History:**
- Mother: Hashimoto thyroiditis, fibromyalgia
- Father: Type 2 diabetes
- Sister: Celiac disease

### Physical Examination
- **Vital Signs:** BP 108/68 mmHg, HR 78 bpm, RR 14, Temp 37.0°C, SpO2 98% RA, BMI 24.2
- **General:** Well-appearing but fatigued-appearing female, no acute distress
- **HEENT:** Mild pharyngeal erythema, small bilateral anterior cervical lymph nodes palpable (< 1 cm, mobile, non-tender)
- **Cardiovascular:** Regular rate and rhythm, no murmurs
- **Respiratory:** Clear to auscultation bilaterally
- **Abdomen:** Soft, non-tender, mild bloating in lower quadrants
- **Musculoskeletal:** No joint swelling, mild tenderness at trapezius and paraspinal muscles bilaterally
- **Neurological:** Cranial nerves II-XII intact, normal strength and sensation, mildly delayed serial 7s

### Workup and Results

**Laboratory Studies:**
| Test | Result | Reference Range |
|------|--------|-----------------|
| CBC with differential | WNL | - |
| CMP | WNL | - |
| TSH | 2.8 mIU/L | 0.4-4.0 mIU/L |
| Free T3 | 2.1 pg/mL | 2.3-4.2 pg/mL |
| Free T4 | 1.0 ng/dL | 0.8-1.8 ng/dL |
| Anti-TPO antibodies | 48 IU/mL | < 35 IU/mL |
| Ferritin | 18 ng/mL | 12-150 ng/mL |
| Vitamin D, 25-OH | 19 ng/mL | 30-100 ng/mL |
| Vitamin B12 | 280 pg/mL | 200-900 pg/mL |
| hs-CRP | 3.8 mg/L | < 1.0 mg/L |
| Cortisol (AM, 8 AM draw) | 8.2 mcg/dL | 6.2-19.4 mcg/dL |
| DHEA-S | 88 mcg/dL | 95-530 mcg/dL |
| Homocysteine | 14.2 umol/L | 5-15 umol/L |
| Omega-3 Index | 3.8% | > 8% optimal |
| IgA tissue transglutaminase | Negative | Negative |

**Imaging/Additional Studies:**
- DUTCH Complete Hormone Test: Suboptimal cortisol awakening response with blunted diurnal curve
- GI-MAP stool analysis: Low Akkermansia muciniphila, elevated zonulin at 88 ng/mL (ref < 60), low secretory IgA
- Heart rate variability (HRV) assessment: Reduced parasympathetic tone, elevated sympathetic dominance

### Clinical Image

![Integrative assessment framework for chronic fatigue](case_01_image.jpg)

*Integrative assessment framework showing the interconnected systems evaluated in chronic fatigue: neuroendocrine, immune, gastrointestinal, mitochondrial, and psychosocial domains. Source: Educational illustration.*

### Diagnosis
**Post-COVID Chronic Fatigue Syndrome with Subclinical Autoimmune Thyroiditis, Micronutrient Deficiencies, and Intestinal Hyperpermeability**

**Key Diagnostic Criteria:**
- Persistent fatigue > 6 months following viral infection with post-exertional malaise
- Cognitive impairment ("brain fog") affecting daily function
- Unrefreshing sleep despite adequate duration
- Elevated anti-TPO antibodies with low-normal free T3 suggesting early Hashimoto thyroiditis
- Suboptimal ferritin, vitamin D deficiency, and low omega-3 index
- Elevated zonulin indicating intestinal hyperpermeability
- Blunted cortisol awakening response suggesting HPA axis dysregulation

### Treatment Plan
1. **Nutritional optimization:** Iron bisglycinate 36 mg daily with vitamin C, vitamin D3 5000 IU daily with K2, methylcobalamin 1000 mcg sublingual daily, omega-3 fatty acids (EPA/DHA) 2 g daily
2. **Gut restoration protocol:** L-glutamine 5 g daily, spore-based probiotics, bone broth or collagen peptides, elimination of gluten for 8-week trial given family history and elevated zonulin
3. **Adrenal support:** Ashwagandha (KSM-66) 600 mg daily, phosphatidylserine 100 mg at bedtime, morning light exposure within 30 minutes of waking
4. **Graduated activity:** Pacing strategy with heart rate monitoring, gentle yoga 3x/week, progressive walking program staying below anaerobic threshold
5. **Mind-body medicine:** Mindfulness-based stress reduction (MBSR) 8-week program, vagal nerve stimulation exercises, sleep hygiene optimization
6. **Monitoring:** Recheck anti-TPO, ferritin, vitamin D, hs-CRP, and free T3 in 12 weeks; refer to integrative medicine physician for ongoing co-management

### Key Learning Points
- Chronic fatigue requires evaluation beyond standard labs; functional markers including ferritin (optimal > 50 ng/mL), free T3, vitamin D, and inflammatory markers provide a more complete picture
- Post-COVID fatigue may involve HPA axis dysregulation, neuroinflammation, and gut-immune disruption that standard workup fails to capture
- Subclinical Hashimoto thyroiditis (elevated anti-TPO with "normal" TSH) can contribute to fatigue, especially when free T3 is suboptimal
- Intestinal hyperpermeability (elevated zonulin) can drive systemic inflammation and immune dysregulation, making gut assessment essential in chronic fatigue
- Integrative treatment plans address root causes across multiple systems simultaneously rather than treating symptoms in isolation

---

## Case 2: Irritable Bowel Syndrome with Mind-Gut Therapy

### Patient Presentation
**Demographics:** 29-year-old male software engineer

**Chief Complaint:** "My stomach has been a mess for three years and it's ruining my life."

**History of Present Illness:**
The patient presents with a three-year history of alternating constipation and diarrhea with associated abdominal pain, bloating, and excessive gas. His symptoms began during a period of intense work stress and a relationship breakup. He reports that abdominal pain is typically crampy, located in the left lower quadrant, and partially relieved by defecation. Bowel habits alternate between 3-4 days of constipation followed by 2-3 days of loose stools (Bristol type 6-7).

He has previously been evaluated with a colonoscopy (normal), celiac panel (negative), and stool studies for infectious etiologies (negative). He was diagnosed with IBS-Mixed type and prescribed dicyclomine, which provided only partial relief. He reports that symptoms significantly worsen with work deadlines, travel, and social eating situations.

He has developed significant food anxiety and has progressively restricted his diet, eliminating dairy, gluten, soy, and most raw vegetables. Despite restrictions, his symptoms persist. He reports disrupted sleep, noting that he frequently wakes at 3-4 AM with abdominal discomfort. He endorses significant anxiety around meals and has begun avoiding social situations involving food.

**Past Medical History:**
- IBS-Mixed type (diagnosed 2 years ago)
- Generalized anxiety disorder
- Lactose intolerance (self-diagnosed)

**Medications:**
- Dicyclomine 20 mg as needed before meals
- Psyllium husk fiber supplement daily
- Probiotic (Lactobacillus/Bifidobacterium blend)

**Social History:**
- Non-smoker, 3-4 cups of coffee daily
- Alcohol: 4-6 beers on weekends
- Sedentary work, sits 10+ hours daily
- High-stress tech job with frequent deadlines
- Restrictive diet due to food fears

**Family History:**
- Mother: IBS, anxiety disorder
- Father: Peptic ulcer disease
- Maternal grandmother: Colon cancer at age 72

### Physical Examination
- **Vital Signs:** BP 122/78 mmHg, HR 82 bpm, RR 16, Temp 36.8°C, SpO2 99% RA, BMI 22.1
- **General:** Thin, anxious-appearing male
- **Abdomen:** Mild distension, tympanic to percussion, tenderness to deep palpation in left lower quadrant, no rebound or guarding, hyperactive bowel sounds, no hepatosplenomegaly
- **Rectal:** Normal tone, no masses, stool guaiac negative
- **Musculoskeletal:** Tense paracervical and trapezius muscles bilaterally
- **Psychiatric:** Anxious affect, speaks rapidly, frequently mentions food fears

### Workup and Results

**Laboratory Studies:**
| Test | Result | Reference Range |
|------|--------|-----------------|
| CBC | WNL | - |
| CMP | WNL | - |
| ESR | 4 mm/hr | 0-15 mm/hr |
| CRP | 0.4 mg/L | < 3.0 mg/L |
| Fecal calprotectin | 28 mcg/g | < 50 mcg/g |
| IgA tTG antibodies | Negative | Negative |
| TSH | 1.9 mIU/L | 0.4-4.0 mIU/L |
| Lactulose breath test | Positive | Negative |
| Fructose breath test | Positive | Negative |
| Cortisol (AM) | 22.1 mcg/dL | 6.2-19.4 mcg/dL |
| Serotonin (whole blood) | 68 ng/mL | 50-220 ng/mL |
| Stool elastase | 410 mcg/g | > 200 mcg/g |
| Secretory IgA (stool) | 188 mcg/mL | 510-2040 mcg/mL |

**Imaging/Additional Studies:**
- Colonoscopy (1 year prior): Normal mucosa, random biopsies negative for microscopic colitis
- Abdominal ultrasound: No gallstones, normal liver and pancreas
- Lactulose breath test: Positive for SIBO with hydrogen peak at 60 minutes
- Validated questionnaires: GAD-7 score 14 (moderate anxiety), PHQ-9 score 8 (mild depression), IBS-SSS score 328 (severe)
- Visceral Sensitivity Index: 24/75 (significant GI-specific anxiety)

### Clinical Image

![The gut-brain axis in IBS](case_02_image.jpg)

*Diagram of the bidirectional gut-brain axis showing vagal nerve communication, enteric nervous system signaling, microbiome-immune interactions, and the role of psychological stress in IBS symptom generation. Source: Educational illustration.*

### Diagnosis
**Irritable Bowel Syndrome - Mixed Type (IBS-M) with Small Intestinal Bacterial Overgrowth (SIBO), GI-Specific Anxiety, and Dysregulated Gut-Brain Axis**

**Key Diagnostic Criteria:**
- Rome IV criteria met: Recurrent abdominal pain at least 1 day/week for > 3 months, associated with defecation, change in stool frequency, and change in stool form
- Positive lactulose breath test confirming SIBO
- Normal inflammatory markers and fecal calprotectin excluding IBD
- Elevated morning cortisol suggesting chronic stress activation
- Low secretory IgA indicating mucosal immune compromise
- High IBS-SSS and Visceral Sensitivity Index scores indicating severe disease with significant brain-gut dysfunction

### Treatment Plan
1. **SIBO eradication:** Rifaximin 550 mg TID for 14 days, followed by partially hydrolyzed guar gum (PHGG) 5 g daily as prokinetic prebiotic
2. **Gut-directed psychotherapy:** Referral for gut-directed hypnotherapy (7-session protocol) targeting visceral hypersensitivity and GI-specific anxiety
3. **Dietary restructuring:** Low-FODMAP elimination diet for 6 weeks with structured reintroduction guided by registered dietitian; gradual caffeine reduction to 1 cup daily; alcohol reduction to 2 drinks/week maximum
4. **Mind-body interventions:** Diaphragmatic breathing exercises before meals (5 minutes), progressive muscle relaxation at bedtime, cognitive behavioral therapy for food-related anxiety
5. **Vagal tone enhancement:** Cold water face immersion, gargling exercises, HRV biofeedback training 3x/week
6. **Prokinetic support:** Post-SIBO treatment low-dose prucalopride 1 mg at bedtime to prevent recurrence; ginger root extract 250 mg before meals
7. **Follow-up:** Repeat breath test at 8 weeks, IBS-SSS and GAD-7 reassessment at 12 weeks, dietitian review at 6 and 12 weeks

### Key Learning Points
- IBS is a disorder of gut-brain interaction (DGBI), not merely a functional bowel problem; treatment must address both the peripheral and central components
- SIBO is present in up to 78% of IBS patients and should be tested for, as eradication can significantly improve symptoms
- Gut-directed hypnotherapy has Level A evidence for IBS with NNT of 4, comparable to any pharmaceutical intervention
- GI-specific anxiety and visceral hypersensitivity are powerful perpetuating factors that standard anxiolytic therapy alone does not adequately address
- Overly restrictive diets can worsen nutritional status and food-related anxiety; structured reintroduction with professional guidance is essential

---

## Case 3: Fibromyalgia with Multimodal Treatment

### Patient Presentation
**Demographics:** 45-year-old female registered nurse

**Chief Complaint:** "I hurt everywhere and no one can figure out why."

**History of Present Illness:**
The patient presents with a 5-year history of widespread musculoskeletal pain that has progressively intensified. She describes the pain as a constant, deep ache affecting her neck, shoulders, back, hips, and legs, rated at 6-8/10 on most days. She reports prominent morning stiffness lasting 60-90 minutes daily. The pain is worsened by cold weather, prolonged standing (required by her job), poor sleep, and emotional stress.

She reports severe sleep disruption, describing difficulty falling asleep and frequent awakenings with a sensation of "never reaching deep sleep." She estimates getting 4-5 hours of fragmented sleep nightly. Daytime fatigue is profound, and she has had to reduce her work schedule from full-time to three 12-hour shifts per week. She also reports cognitive difficulties including poor concentration and memory, headaches (2-3 per week), paresthesias in her hands, and temperature sensitivity.

She has seen a rheumatologist who performed extensive workup including ANA, RF, anti-CCP, and inflammatory markers, all of which were negative. She has tried gabapentin (stopped due to weight gain and dizziness), amitriptyline (stopped due to excessive sedation), and duloxetine (partial benefit at 60 mg but still symptomatic). She expresses frustration with the medical system and feels her pain is not taken seriously.

**Past Medical History:**
- Fibromyalgia (diagnosed 3 years ago)
- Chronic migraine
- Temporomandibular joint dysfunction
- Major depressive episode (5 years ago, in remission)
- Childhood adverse experiences (emotional neglect)

**Medications:**
- Duloxetine 60 mg daily
- Sumatriptan 50 mg PRN for migraines
- Cyclobenzaprine 5 mg at bedtime PRN
- Ibuprofen 400 mg PRN (taking daily)

**Social History:**
- Non-smoker, no alcohol
- Works as an RN on a medical-surgical floor (3x12-hour shifts)
- Divorced, single mother of two children (ages 10 and 13)
- Limited social support
- No regular exercise due to pain and fatigue

**Family History:**
- Mother: Fibromyalgia, depression
- Sister: Chronic fatigue syndrome
- Father: Alcoholism, chronic pain

### Physical Examination
- **Vital Signs:** BP 134/82 mmHg, HR 76 bpm, RR 14, Temp 36.6°C, SpO2 98% RA, BMI 28.4
- **General:** Appears older than stated age, moves slowly and stiffly, pain behaviors noted with position changes
- **HEENT:** Tenderness over bilateral temporomandibular joints, limited jaw opening (32 mm)
- **Neck:** Restricted ROM in all planes, prominent trapezius and SCM trigger points
- **Musculoskeletal:** Widespread tenderness at all 18 classic tender points (16/18 positive), no joint swelling or erythema, full ROM in major joints but pain at end range, multiple myofascial trigger points in trapezius, rhomboids, piriformis, and gluteus medius
- **Neurological:** Normal strength 5/5 throughout, intact sensation, DTRs 2+ symmetric, allodynia to light touch over upper trapezius bilaterally
- **Psychiatric:** Flat affect, tearful when discussing impact on parenting, endorses frustration and hopelessness about condition

### Workup and Results

**Laboratory Studies:**
| Test | Result | Reference Range |
|------|--------|-----------------|
| ANA | Negative | Negative |
| RF | < 10 IU/mL | < 14 IU/mL |
| Anti-CCP | < 20 U/mL | < 20 U/mL |
| ESR | 6 mm/hr | 0-20 mm/hr |
| CRP | 0.8 mg/L | < 3.0 mg/L |
| CBC | WNL | - |
| CMP | WNL | - |
| TSH | 2.4 mIU/L | 0.4-4.0 mIU/L |
| Vitamin D, 25-OH | 14 ng/mL | 30-100 ng/mL |
| Ferritin | 22 ng/mL | 12-150 ng/mL |
| Magnesium (RBC) | 3.8 mg/dL | 4.2-6.8 mg/dL |
| HbA1c | 5.6% | < 5.7% |
| Insulin (fasting) | 14.2 mU/L | 2.6-11.1 mU/L |
| Substance P (research) | Elevated | - |

**Imaging/Additional Studies:**
- Polysomnography: Reduced N3 (deep) sleep to 4% of total sleep time (normal > 15%), alpha-wave intrusion into delta sleep (alpha-delta sleep anomaly), AHI 2.1 (no significant sleep apnea), PLM index 8
- MRI cervical spine: Mild degenerative changes at C5-C6 without neural compression
- Quantitative sensory testing: Lowered pressure pain thresholds diffusely, temporal summation present (wind-up), impaired conditioned pain modulation
- ACE score: 4/10 (significant adverse childhood experiences)
- Fibromyalgia Impact Questionnaire (FIQ): 72/100 (severe impact)
- Central Sensitization Inventory: 58/100 (above 40 indicates central sensitization)

### Clinical Image

![Central sensitization in fibromyalgia](case_03_image.jpg)

*Illustration of central sensitization mechanisms in fibromyalgia showing amplified pain signaling in the dorsal horn, descending inhibitory pathway dysfunction, neuroglial activation, and the overlap between fibromyalgia, chronic fatigue, and TMJ dysfunction. Source: Educational illustration.*

### Diagnosis
**Fibromyalgia with Central Sensitization, Alpha-Delta Sleep Anomaly, Vitamin D Deficiency, Magnesium Deficiency, and Early Insulin Resistance**

**Key Diagnostic Criteria:**
- 2016 Modified ACR criteria met: Widespread Pain Index (WPI) 14/19, Symptom Severity Scale (SSS) 10/12, symptoms present > 3 months
- Central sensitization confirmed by quantitative sensory testing (temporal summation, impaired conditioned pain modulation)
- Alpha-delta sleep anomaly on polysomnography explaining unrefreshing sleep
- Normal inflammatory and autoimmune markers excluding systemic rheumatic disease
- Significant micronutrient deficiencies (vitamin D, magnesium) and emerging metabolic dysfunction (fasting hyperinsulinemia)

### Treatment Plan
1. **Pharmacological optimization:** Increase duloxetine to 90 mg daily (if tolerated), add low-dose naltrexone (LDN) starting at 1.5 mg at bedtime titrating to 4.5 mg over 4 weeks for neuroinflammation modulation, discontinue daily ibuprofen (peripheral analgesics minimally effective in central pain)
2. **Sleep restoration:** Trazodone 50 mg at bedtime for N3 sleep enhancement, strict sleep hygiene protocol, weighted blanket trial, evening magnesium glycinate 400 mg
3. **Nutritional correction:** Vitamin D3 50,000 IU weekly for 8 weeks then 5,000 IU daily maintenance, magnesium glycinate 400 mg BID, anti-inflammatory dietary pattern (Mediterranean diet focus), reduce refined carbohydrates to address insulin resistance
4. **Movement therapy:** Aquatic therapy 2x/week (warm water pool), tai chi program 2x/week (evidence-based for fibromyalgia), graduated walking program with pacing strategy
5. **Pain neuroscience education:** Structured 4-session program explaining central sensitization, neuroplasticity of pain, and the distinction between hurt and harm
6. **Trauma-informed care:** Referral for somatic experiencing therapy given ACE score of 4 and trauma history, mindfulness-based stress reduction (MBSR) 8-week program
7. **Myofascial therapy:** Trigger point dry needling for trapezius, piriformis, and gluteus medius, self-myofascial release instruction with foam roller
8. **Follow-up:** FIQ reassessment at 8 and 16 weeks, sleep study follow-up at 12 weeks, metabolic panel and insulin at 12 weeks, vitamin D and magnesium levels at 8 weeks

### Key Learning Points
- Fibromyalgia is a central sensitization syndrome with demonstrable neurobiological abnormalities including altered pain processing, neuroglial activation, and disrupted descending inhibition, not a diagnosis of exclusion
- Alpha-delta sleep anomaly (alpha wave intrusion into N3 sleep) is found in up to 80% of fibromyalgia patients and is a key driver of symptom severity; addressing sleep architecture is critical
- Low-dose naltrexone (LDN) modulates neuroinflammation via toll-like receptor 4 antagonism on microglia and has growing evidence in fibromyalgia with minimal side effects
- Adverse childhood experiences (ACEs) are significantly associated with fibromyalgia risk through persistent HPA axis and autonomic nervous system dysregulation; trauma-informed care should be integrated
- Multimodal treatment combining pharmacology, movement therapy, pain neuroscience education, and psychosocial interventions consistently outperforms any single-modality approach in fibromyalgia